(Q50944465)

25 March 2018

title

The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy? (English)

1 reference

25 March 2018

0 references

Ito T

1

1 reference

25 March 2018

Nishimura C

2

1 reference

25 March 2018

Takahashi Y

3

1 reference

25 March 2018

Saito T

4

1 reference

25 March 2018

Omori Y

5

1 reference

25 March 2018

publication date

1 June 1997

1 reference

25 March 2018

Diabetes Research and Clinical Practice

published in

1 reference

25 March 2018

volume

36

1 reference

25 March 2018

issue

3

1 reference

25 March 2018

page(s)

161-167

1 reference

25 March 2018

Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Pathology and pathogenetic mechanisms of diabetic neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Tolrestat in the Primary Prevention of Diabetic Neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Immunoassay of human aldose reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Standardization of hemoglobinometry II. The hemiglobincyanide method

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Report and recommendations of the San Antonio conference on diabetic neuropathy. Consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Identification of a sorbitol permease in human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Reduced erythrocyte deformability in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Reversible sodium pump defect and swelling in the diabetic rat erythrocyte: effects on filterability and implications for microangiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

Galactosemic neuropathy in transgenic mice for human aldose reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900046-6

7 January 2021

10.1016/S0168-8227(97)00046-6

Identifiers

DOI

1 reference

25 March 2018

1 reference

25 March 2018